Scarica l'app Stockscreener
2.24
4.27%
-0.10
Dopo l'orario di chiusura:
2.28
0.04
+1.79%
Precedente Chiudi:
$2.34
Aprire:
$2.3
Volume 24 ore:
73,858
Relative Volume:
0.23
Capitalizzazione di mercato:
$6.90M
Reddito:
-
Utile/perdita netta:
$-29.77M
Rapporto P/E:
-0.1464
EPS:
-15.2954
Flusso di cassa netto:
$-24.23M
1 W Prestazione:
-7.05%
1M Prestazione:
-42.71%
6M Prestazione:
-76.11%
1 anno Prestazione:
-92.28%
Intervallo 1D:
$2.24
$2.3491
Intervallo di 1 settimana:
$2.22
$2.49
Portata 52W:
$2.22
$33.00
Moleculin Biotech Inc Stock (MBRX) Company Profile
Nome
Moleculin Biotech Inc
Settore
Industria
Telefono
713-300-5160
Indirizzo
5300 MEMORIAL DRIVE, HOUSTON, TX
Compare MBRX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MBRX
Moleculin Biotech Inc
|
2.24 | 7.21M | 0 | -29.77M | -24.23M | -15.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-09 | Ripresa | H.C. Wainwright | Buy |
| 2025-02-12 | Downgrade | Maxim Group | Buy → Hold |
| 2022-07-18 | Ripresa | Oppenheimer | Outperform |
Moleculin Biotech Inc Borsa (MBRX) Ultime notizie
Moleculin Announces Closing of up to $16.5 Million Public Offering - Quantisnow
MBRX Should I Buy - Intellectia AI
MBRX PE Ratio & Valuation, Is MBRX Overvalued - Intellectia AI
Moleculin Biotech (MBRX) seeks OK for 6.37M warrants, $15.3M proceeds - Stock Titan
Why Did MBRX Stock Climb 14% Today? - Stocktwits
Moleculin Biotech Inc. (MBRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Is Moleculin Biotech Inc. forming higher highs and higher lowsJuly 2025 Reactions & Community Trade Idea Sharing Platform - mfd.ru
Moleculin Biotech Raises Capital via Inducement Warrant Agreements - TipRanks
Why Moleculin Biotech Inc. stock remains on buy listsDollar Strength & Daily Entry Point Trade Alerts - mfd.ru
Moleculin Biotech Secures Up To $8.3 Million Via Warrant Exercise; Issues 300% Series H Warrants - TradingView
Moleculin Biotech Exercises Warrants for $8.3M - Intellectia AI
Moleculin Biotech raises $8.3 million through warrant exercise By Investing.com - Investing.com Canada
Moleculin shares slide sharply after warrant exercise deal - MSN
Aug Intraday: Can Moleculin Biotech Inc maintain sales growth2025 Price Momentum & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Moleculin Stock Plunges On $8.3 Million Warrant Exercise - Nasdaq
Moleculin Biotech stock plunges after warrant exercise agreement By Investing.com - Investing.com Nigeria
Moleculin Biotech stock plunges after warrant exercise agreement - Investing.com South Africa
Moleculin Biotech raises $8.3 million through warrant exercise - Investing.com
Moleculin Announces Exercise of Warrants for $8.3 Million Gross Proceeds - The Manila Times
Moleculin Biotech, Inc. Announces Agreement for Immediate Exercise of Warrants to Raise Approximately $8.3 Million - Quiver Quantitative
Moleculin reports promising early data in pivotal AML treatment trial By Investing.com - Investing.com India
Moleculin Biotech Issues New Investor Corporate Presentation - TipRanks
Moleculin Biotech (MBRX) Nears Key Milestone in Leukemia Trial P - GuruFocus
Moleculin Biotech stock rises as AML drug trial shows promising results - Investing.com Nigeria
Moleculin Biotech stock rises as AML drug trial shows promising results By Investing.com - Investing.com Canada
Moleculin Reports Positive Progress in MIRACLE AML Trial - TipRanks
Moleculin reports promising early data in pivotal AML treatment trial - Investing.com
Moleculin reports 40% preliminary CRc in MIRACLE trial; 35 treated, 45-subject unblinding on track - TradingView
Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30) - GlobeNewswire
Moleculin receives patent allowance in Japan for Annamycin preparation method - Investing.com India
Moleculin Biotech Receives Patent Allowance from Japan Patent Office - Intellectia AI
Profit Recap: What are Moleculin Biotech Incs earnings expectations2025 Dividend Review & Low Risk High Win Rate Picks - baoquankhu1.vn
Moleculin Biotech stock rises after securing key Japanese patent - Investing.com
Moleculin Biotech stock rises after securing key Japanese patent By Investing.com - Investing.com India
Moleculin Biotech Says Japan Patent Office Issues Notice of Allowance for Patent Covering Annamycin; Shares Rise Pre-Bell - marketscreener.com
Moleculin Biotech (MBRX) Gains Japanese Patent Progress for Lipo - GuruFocus
Moleculin Gains Japanese Patent Allowance for Annamycin - TipRanks
Moleculin Announces Notice of Allowance for Japanese Patent Covering Annamycin - The Manila Times
Moleculin Biotech, Inc. Receives Notice of Allowance for Japanese Patent on Liposomal Annamycin Preparation Methods - Quiver Quantitative
Can Moleculin Biotech Inc. deliver consistent dividendsJuly 2025 Patterns & Reliable Intraday Trade Alerts - mfd.ru
Moleculin launches CEO Corner to enhance investor communication By Investing.com - Investing.com India
Moleculin Biotech Inc Azioni (MBRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Moleculin Biotech Inc Azioni (MBRX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| KLEMP WALTER V | CEO and President |
Jun 23 '25 |
Buy |
0.37 |
675,675 |
250,000 |
743,607 |
3.69%
0.68%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):